About Mitotherapeutix
Mitotherapeutix is a private company based in Woodbridge, Connecticut. It has reported $2,997,643 raised in two offerings on Form D since October 2016. Its chief executive is John Talley.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Dec 12, 2017 | Dec 28, 2017amended May 22, 2025 | $2,967,643fully sold | 5 | $593K | Debt, Options, Securities on exerciseRule 506(b) | Form D/A ↗2 earlier filings |
| Sep 14, 2016 | Oct 3, 2016 | $30,000fully sold | 1 | $30,000 | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Total, two offerings | $2,997,643 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Mitotherapeutix's Form D filed May 22, 2025.
Fenel Eloi
Director
Also a managing partner, P&M capital partners, director at Terrestrial and a director at Ultivue and VIC Technology Venture Development.
RH
Robert Hemley
Executive officer and director
RH
Robert Hennessey
Executive officer and director
JT
John Talley
Chief Executive Officer and director
DW
Daniel Wagner
Director